亚洲精品综合日韩中文字幕网站_精品综合久久久久97_中文在线天堂网www_久久精品免费一区二区三区_91久久国产综合精品女同国语_久久资源总站在线国产成人

Claudin 18.2 monoclonal antibodies are a promising class of therapeutic agents targeting the Claudin 18.2 protein, a tight junction protein that is highly expressed in various cancers, including gastric, pancreatic, and ovarian cancers. In normal tissues, Claudin 18.2 is predominantly expressed in differentiated gastric mucosal cells, but its upregulation in tumor cells makes it an attractive target for cancer therapy. These monoclonal antibodies, such as Zolbetuximab, work by binding specifically to the extracellular domain of Claudin 18.2, inducing antibody-dependent cellular cytotoxicity （ADCC） and complement-dependent cytotoxicity （CDC） to kill cancer cells.